Literature DB >> 29028368

A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices.

Rakesh Nagarajan, Angela N Bartley, Julia A Bridge, Lawrence J Jennings, Suzanne Kamel-Reid, Annette Kim, Alexander J Lazar, Neal I Lindeman, Joel Moncur, Alex J Rai, Mark J Routbort, Patricia Vasalos, Jason D Merker.   

Abstract

CONTEXT: - Detection of acquired variants in cancer is a paradigm of precision medicine, yet little has been reported about clinical laboratory practices across a broad range of laboratories.
OBJECTIVE: - To use College of American Pathologists proficiency testing survey results to report on the results from surveys on next-generation sequencing-based oncology testing practices.
DESIGN: - College of American Pathologists proficiency testing survey results from more than 250 laboratories currently performing molecular oncology testing were used to determine laboratory trends in next-generation sequencing-based oncology testing.
RESULTS: - These presented data provide key information about the number of laboratories that currently offer or are planning to offer next-generation sequencing-based oncology testing. Furthermore, we present data from 60 laboratories performing next-generation sequencing-based oncology testing regarding specimen requirements and assay characteristics. The findings indicate that most laboratories are performing tumor-only targeted sequencing to detect single-nucleotide variants and small insertions and deletions, using desktop sequencers and predesigned commercial kits. Despite these trends, a diversity of approaches to testing exists.
CONCLUSIONS: - This information should be useful to further inform a variety of topics, including national discussions involving clinical laboratory quality systems, regulation and oversight of next-generation sequencing-based oncology testing, and precision oncology efforts in a data-driven manner.

Entities:  

Mesh:

Year:  2017        PMID: 29028368     DOI: 10.5858/arpa.2016-0542-CP

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study.

Authors:  T Spence; N Stickle; C Yu; H Chow; H Feilotter; B Lo; E McCready; B Sadikovic; L L Siu; P L Bedard; T L Stockley
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

2.  A Validation Framework for Somatic Copy Number Detection in Targeted Sequencing Panels.

Authors:  Raghu Chandramohan; Jacquelyn Reuther; Ilavarasi Gandhi; Horatiu Voicu; Karla R Alvarez; Sharon E Plon; Dolores H Lopez-Terrada; Kevin E Fisher; D Williams Parsons; Angshumoy Roy
Journal:  J Mol Diagn       Date:  2022-04-26       Impact factor: 5.341

3.  Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Authors:  Jason D Merker; Kelly Devereaux; A John Iafrate; Suzanne Kamel-Reid; Annette S Kim; Joel T Moncur; Stephen B Montgomery; Rakesh Nagarajan; Bryce P Portier; Mark J Routbort; Craig Smail; Lea F Surrey; Patricia Vasalos; Alexander J Lazar; Neal I Lindeman
Journal:  Arch Pathol Lab Med       Date:  2018-10-30       Impact factor: 5.534

4.  Immunohistochemical Validation of Rare Tissues and Antigens With Low Frequency of Occurrence: Recommendations From The Anatomic Pathology Patient Interest Association (APPIA).

Authors:  Robert L Lott; Peter V Riccelli; Elizabeth A Sheppard; Keith A Wharton; Eric E Walk; George Kennedy; Bryce Portier
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021 May-Jun 01

Review 5.  Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.

Authors:  Diana N Ionescu; Tracy L Stockley; Shantanu Banerji; Christian Couture; Cheryl A Mather; Zhaolin Xu; Normand Blais; Parneet K Cheema; Quincy S-C Chu; Barbara Melosky; Natasha B Leighl
Journal:  Curr Oncol       Date:  2022-07-15       Impact factor: 3.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.